{"schema_version":"secwatch.filing_event.v1","accession":"0000939767-23-000112","form_type":"8-K","ticker":"EXEL","cik":"0000939767","company_name":"EXELIXIS, INC.","filed_at":"2023-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.466806+00:00","generated_at":"2026-06-09T03:56:54.853028+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Exelixis Q3 revenue up 15% to $471.9M but GAAP net income drops to $1.0M from $73.2M","bullets":["Q3 total revenues $471.9M (up 14.6% YoY); net product rev $426.5M (up 16.4% YoY).","GAAP net income $1.0M ($0.00 EPS) vs $73.2M ($0.23 EPS) in Q3 2022; non-GAAP net income $32.1M ($0.10 EPS).","R&D expenses surged to $332.6M from $198.8M, driven by license/collaboration costs and pipeline investments.","Positive phase 3 data from CONTACT-02 (prostate) and CABINET (neuroendocrine tumors) studies for cabozantinib.","Appointed Dr. Amy Peterson as CMO in August; in-licensed XL309 (USP1 inhibitor) from Insilico Medicine."],"urls":{"canonical":"https://secwatch.observer/filing/0000939767-23-000112","json":"https://secwatch.observer/filing/0000939767-23-000112.json","markdown":"https://secwatch.observer/filing/0000939767-23-000112.md","text":"https://secwatch.observer/filing/0000939767-23-000112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/939767/000093976723000112/0000939767-23-000112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/939767/000093976723000112/exel-20231101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T03:56:54.853028+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b873c87db6ae9c1511e7ccee458cd7227ccfd8af","claim":"EXELIXIS, INC. reported quarter ended September 30, 2023 results: revenue $471.9 million, net income $1.0 million, or $0.00 per share, basic and diluted.","evidence_excerpt":"Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update - Total Revenues of $471.9 million, Cabozantinib Franchise U.S. Net Product Revenues of $426.5 million -","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/939767/000093976723000112/0000939767-23-000112-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2023"},{"label":"Revenue","value":"$471.9 million"},{"label":"Net income","value":"$1.0 million, or $0.00 per share, basic and diluted"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}